Chronic myelogenous leukemia: A review and update of therapeutic strategies

Guillermo Garcia-Manero, Stefan Faderl, Susan O'Brien, Jorge Cortes, Moshe Talpaz, Hagop M. Kantarjian

Research output: Contribution to journalReview article

Abstract

The prognosis of patients with chronic myelogenous leukemia (CML) has significantly improved over the last 20 years. Whereas the median survival durations were 4-5 years in the era of hydroxyurea therapy, the introduction of interferon-a, both alone and in combination with cytosine arabinoside, has nearly doubled these numbers. However, the development of imatinib, a BCR-ABL selective tyrosine kinase inhibitor, represents one of the biggest leaps forward in the treatment of CML and will probably have a significant impact on the course and potential one of CML. Here, we review the biology of CML, its clinical features, and therapeutic options in this disease.

Original languageEnglish (US)
Pages (from-to)437-457
Number of pages21
JournalCancer
Volume98
Issue number3
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hydroxyurea
Cytarabine
Therapeutics
Protein-Tyrosine Kinases
Interferons
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Garcia-Manero, G., Faderl, S., O'Brien, S., Cortes, J., Talpaz, M., & Kantarjian, H. M. (2003). Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer, 98(3), 437-457. https://doi.org/10.1002/cncr.11520

Chronic myelogenous leukemia : A review and update of therapeutic strategies. / Garcia-Manero, Guillermo; Faderl, Stefan; O'Brien, Susan; Cortes, Jorge; Talpaz, Moshe; Kantarjian, Hagop M.

In: Cancer, Vol. 98, No. 3, 01.08.2003, p. 437-457.

Research output: Contribution to journalReview article

Garcia-Manero, G, Faderl, S, O'Brien, S, Cortes, J, Talpaz, M & Kantarjian, HM 2003, 'Chronic myelogenous leukemia: A review and update of therapeutic strategies', Cancer, vol. 98, no. 3, pp. 437-457. https://doi.org/10.1002/cncr.11520
Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer. 2003 Aug 1;98(3):437-457. https://doi.org/10.1002/cncr.11520
Garcia-Manero, Guillermo ; Faderl, Stefan ; O'Brien, Susan ; Cortes, Jorge ; Talpaz, Moshe ; Kantarjian, Hagop M. / Chronic myelogenous leukemia : A review and update of therapeutic strategies. In: Cancer. 2003 ; Vol. 98, No. 3. pp. 437-457.
@article{5eb53bf5db284e2f9f4c7c97dbafc48d,
title = "Chronic myelogenous leukemia: A review and update of therapeutic strategies",
abstract = "The prognosis of patients with chronic myelogenous leukemia (CML) has significantly improved over the last 20 years. Whereas the median survival durations were 4-5 years in the era of hydroxyurea therapy, the introduction of interferon-a, both alone and in combination with cytosine arabinoside, has nearly doubled these numbers. However, the development of imatinib, a BCR-ABL selective tyrosine kinase inhibitor, represents one of the biggest leaps forward in the treatment of CML and will probably have a significant impact on the course and potential one of CML. Here, we review the biology of CML, its clinical features, and therapeutic options in this disease.",
author = "Guillermo Garcia-Manero and Stefan Faderl and Susan O'Brien and Jorge Cortes and Moshe Talpaz and Kantarjian, {Hagop M.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1002/cncr.11520",
language = "English (US)",
volume = "98",
pages = "437--457",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Chronic myelogenous leukemia

T2 - A review and update of therapeutic strategies

AU - Garcia-Manero, Guillermo

AU - Faderl, Stefan

AU - O'Brien, Susan

AU - Cortes, Jorge

AU - Talpaz, Moshe

AU - Kantarjian, Hagop M.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - The prognosis of patients with chronic myelogenous leukemia (CML) has significantly improved over the last 20 years. Whereas the median survival durations were 4-5 years in the era of hydroxyurea therapy, the introduction of interferon-a, both alone and in combination with cytosine arabinoside, has nearly doubled these numbers. However, the development of imatinib, a BCR-ABL selective tyrosine kinase inhibitor, represents one of the biggest leaps forward in the treatment of CML and will probably have a significant impact on the course and potential one of CML. Here, we review the biology of CML, its clinical features, and therapeutic options in this disease.

AB - The prognosis of patients with chronic myelogenous leukemia (CML) has significantly improved over the last 20 years. Whereas the median survival durations were 4-5 years in the era of hydroxyurea therapy, the introduction of interferon-a, both alone and in combination with cytosine arabinoside, has nearly doubled these numbers. However, the development of imatinib, a BCR-ABL selective tyrosine kinase inhibitor, represents one of the biggest leaps forward in the treatment of CML and will probably have a significant impact on the course and potential one of CML. Here, we review the biology of CML, its clinical features, and therapeutic options in this disease.

UR - http://www.scopus.com/inward/record.url?scp=0038299199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038299199&partnerID=8YFLogxK

U2 - 10.1002/cncr.11520

DO - 10.1002/cncr.11520

M3 - Review article

C2 - 12879460

AN - SCOPUS:0038299199

VL - 98

SP - 437

EP - 457

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -